No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Revlimid (lenalidomide) is an oral immunomodulatory drug used in the treatment of multiple myeloma, a type of cancer that affects the bone marrow. It is also used to treat mantle cell lymphoma, a type of non-Hodgkin's lymphoma. Revlimid works by targeting certain proteins in the body that are involved in the growth and spread of cancer cells. It is often used in combination with other drugs, such as dexamethasone, to increase its effectiveness.
Revlimid is a part of the oncology drug market, which includes drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and colorectal cancer. Oncology drugs are typically divided into two categories: targeted therapies and chemotherapy. Targeted therapies are drugs that target specific proteins or pathways involved in the growth and spread of cancer cells, while chemotherapy is a more general approach that uses drugs to kill cancer cells.
The oncology drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Celgene, Novartis, Pfizer, Merck, and Bristol-Myers Squibb. These companies offer a range of treatments, from targeted therapies to chemotherapy, to meet the needs of patients with different types of cancer. Show Less Read more
